Navigation Links
Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
Date:10/27/2008

WTA2 Kits Offer Rapid, Robust Amplification of Partially Degraded RNA

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of its TransPlex(R) Whole Transcriptome Amplification (WTA2) technology (http://www.sigma.com/wta). TransPlex technology is believed to be the fastest, most sensitive and robust method available for amplifying total RNA from a variety of sample tissue sources such as animals, plants, and microorganisms. Optimized for formalin-fixed and paraffin-embedded tissue samples, WTA2 is the second addition to the patent-pending suite of WTA products designed to study RNA in vitro.

"Sigma-Aldrich is committed to bringing best-in-class technologies to the genomic research community," said Helge Bastian, Vice President of Marketing for Sigma-Aldrich's Research Biotech Business Unit. "The TransPlex(R) Whole Transcriptome Amplification product line adds an important tool for researchers who work with limited quantity and quality of RNA samples."

The TransPlex WTA technology creates a cDNA library from total RNA template and then amplifies the cDNA library in a single PCR reaction. The TransPlex reagents and protocols, optimized to ensure clonal and stochastic amplification of all expressed genes and exons, allow RNA samples to be amplified 1,000-10,000 fold in less than four hours. Sigma-Aldrich's WTA2 technology is highly robust, designed for use with RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue derived from tumor samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies,
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... MD (PRWEB) July 29, 2014 ... a vaccine pioneer in the biotechnology industry, announced ... Newport Coast Securities, Inc. to explore financing opportunities ... LAMP-vax technology, a breakthrough vaccine platform with the ... market. The company exclusively licensed the well-established LAMP ...
(Date:7/29/2014)... ST. LOUIS , July 29, 2014  Sigma-Aldrich ... global water and energy use, increased its investment in ... community service around the world last year, the Company ... Report: What if Science Changed the World? ... has earned several honors for being a responsible corporate ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... 2014 Eppendorf Centrifuge 5427 R ... Eppendorf 5427 R is geared towards high-end applications like ... is targeted towards work requiring high sample throughput. Pipette.com ... it compliments their extensive 16, 48, and 64 multichannel ... tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... 30, 2011 Merrimack Pharmaceuticals, Inc. announced today ... an oligoclonal therapeutic consisting of a mixture of ... encapsulation of irinotecan, at the 14th World Conference ... 7, 2011, in Amsterdam, The Netherlands. ...
... 29, 2011 Dendreon Corporation (Nasdaq: ... and Drug Administration (FDA) approved its Los Angeles cancer ... increase the availability of PROVENGE ® (sipuleucel-T) across ... with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone ...
... Olive Branch Fund: A Thisbe and Noah Scott Legacy, ... today announced its first funding award to Kevin Eggan, ... at Harvard University.  The award will support Dr. Eggan,s ... that affect it.  Dr. Eggan is a leading researcher ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
(Date:7/29/2014)... book that brings together two of the major disciplines ... of insect fossils through stunning photographs and unique illustrations. ... E Jepson, details the incredible preservation and diversity of ... for what these remarkable fossils can tell us about ... of our planet. Like the mosquito in Jurassic Park, ...
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... States have a circulatory problem of the legs called ... even require surgery in serious cases. This disease can ... limb amputation. , At The University of Texas Health ... a non-surgical preventative treatment in a mouse model of ... circulation. Their proof-of-concept study appears in the journal ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... pollution from power plants and automobiles is destroying the ... pollinating insects to follow scent trails to their source, ... partially explain why wild populations of some pollinators, particularly ... declining in several areas of the world, including California ...
... may be so old that dinosaurs once lumbered along its ... of Colorado at Boulder and the California Institute of Technology. ... to show the Grand Canyon may have formed more than ... 40 million to 50 million years. The researchers gathered ...
... Researchers from all over the world have been ... mouth and saliva cells to carry out the DNA analysis., ... (director of the Laboratory of Genetic Identification of the ... by the court in cases of paternity tests, for the ...
Cached Biology News:Flowers' fragrance diminished by air pollution, University of Virginia study indicates 2Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Fraud attempt in a paternity test modifies action protocol in DNA tests 2
... by John M. Walker (1996) • ... analytical techniques for studying proteins and ... contains detailed, step-by-step instruction, timesaving troubleshooting ... comprehensive lists of reagents and suppliers. ...
...
ANTI S. ENT TOX BC2D...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
Biology Products: